ACADIA Pharmaceuticals (ACAD) stock had a bullish inflow of $7.25 million worth of trades on uptick and an outflow of $5.56 million in downticks on Thursday. The total uptick to downtick ratio stood at 1.3. The net money flow into the stock was $1.69 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $2.17 million. An inflow of $0.8 million block trade was recorded on downticks. $2.97 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 3.7 in favor of the bulls. However, ACADIA Pharmaceuticals (ACAD) stock traded down $0.23 , and reached $33.38, a drop of -0.68% over the previous day. On a weekly basis, the stock is -2.54%, over the previous weeks close.
ACADIA Pharmaceuticals (ACAD) : Average target price received by ACADIA Pharmaceuticals (ACAD) is $46.44 with an expected standard deviation of $6.65. The most aggressive target on the stock is $55, whereas the most downbeat target is $35. 9 financial analysts are currently covering the stock. The stock has recorded a 20-day Moving Average of 5.7% and the 50-Day Moving Average is 0.89%.
ACADIA Pharmaceuticals (NASDAQ:ACAD): The stock opened at $33.72 on Thursday but the bulls could not build on the opening and the stock topped out at $34.34 for the day. The stock traded down to $32.95 during the day, due to lack of any buying support eventually closed down at $33.51 with a loss of -0.30% for the day. The stock had closed at $33.61 on the previous day. The total traded volume was 1,122,043 shares.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.